Inhibitory Effect of Ethyl Acetate Extract of Aristolochia Yunnanensis on Cardiac Fibrosis Through Extracellular Signal-Regulated Kinases 1/2 and Transforming Growth Factor Β/small Mother Against Decapentaplegic Signaling Pathways

Weiwei Shao,Dong Li,Jin Peng,Shaorui Chen,Chun Zhou,Zhongbin Cheng,Yang Vu,Hong Li,Cuixian Li,Yan You,Yunzi Ma,Peiqing Liu,Sheng Yin,Xiaoyan Shen

DOI: https://doi.org/10.1016/j.trsl.2013.09.013

IF: 10.171

2014-01-01

Translational Research

Abstract:Aristolochia yunnanensis, known as Nan Mu Xiang in traditional Chinese medicine, has long been used to treat hypertension and chest pain. In this study, the effect of ethyl acetate extract of Nan Mu Xiang (NMX) on cardiac fibrosis was assessed in vitro by cultured adult rat cardiac fibroblasts with angiotensin II (AngII) stimulation, and in vivo by rats with abdominal aorta constriction (AAC). In cultured adult rat cardiac fibroblasts stimulated by AngII, NMX inhibited cardiac fibroblast proliferation, reduced the expression of fibronectin, α-smooth muscle actin (α-SMA), and transforming growth factor β (TGF-β) in a dose-dependent manner; and suppressed AngII-induced phosphorylation of extracellular signal-regulated kinase (ERK)1/2, C- rapidly accelerated fibrosarcoma (C-Raf), and small mother against decapentaplegic (Smad) 2. Similar results were also observed in AAC rats with intraperitoneal injection of NMX, which not only ameliorated myocardial fibrosis, but also improved cardiac function. The therapeutic effect of NMX on myocardial fibrosis is attributed mainly to the inhibition of ERK and the TGF-β/Smad signaling pathways. NMX may be a promising potential drug candidate for myocardial fibrosis.